<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569658</url>
  </required_header>
  <id_info>
    <org_study_id>Rush TXA TSA</org_study_id>
    <nct_id>NCT02569658</nct_id>
  </id_info>
  <brief_title>Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty</brief_title>
  <official_title>Investigation of the Blood Sparing Properties of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare intravenous Tranexamic Acid (TXA) versus normal saline placebo to determine
      whether or not TXA administration reduces blood loss, decrease in hemoglobin, and rate of
      transfusions following anatomic and reverse total shoulder arthroplasty (TSA) surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anatomic and reverse total shoulder arthroplasty (TSA) is associated with the risk of
      moderate to significant blood loss that can lead to transfusions. Average estimated blood
      loss has been reported in the range of 354 to 361 mL intraoperatively, not accounting for
      additional postoperative blood loss postoperatively in surgical drains. Transfusion rates
      have been reported to range from 2.4% to 9.5% in recent studies, with rates over 30% for
      revision cases. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that is an
      established method of reducing blood loss and transfusion requirement for patients
      undergoing total hip and knee arthroplasty. TXA can be administered intravenously, topically
      (intraarticularly), or orally, with most available literature addressing intravenous and
      topical administration. Systematic reviews and meta-analyses of the total hip and knee
      arthroplasty literature demonstrate approximately a 30% decrease in blood loss and 50%
      decrease in transfusion rate with topical or intravenous administration of TXA compared to
      placebo. Moreover, the literature demonstrates no increased rate of thromboembolic or other
      complications associated with TXA administration for hip and knee arthroplasty.

      Despite proven efficacy in the hip and knee arthroplasty literature, there have been no
      studies analyzing the ability of TXA to reduce blood loss and transfusion rate following
      TSA.

      Purpose of the study is to compare intravenous Tranexamic Acid (TXA) versus normal saline
      placebo to determine whether or not TXA administration reduces blood loss, decrease in
      hemoglobin, and rate of transfusions following anatomic and reverse total shoulder
      arthroplasty (TSA) surgeries. With the hypothesis that intravenous TXA will reduce blood
      loss following TSA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative blood loss</measure>
    <time_frame>Average of 3 days post-operatively</time_frame>
    <description>Equated based on the patient's predicted blood volume and change in hemoglobin from the pre-operative level to the lowest post-operative level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative reduction in hemoglobin</measure>
    <time_frame>Average of 3 days post-operatively</time_frame>
    <description>Measured as the pre-operative hemoglobin minus the lowest post-operative hemoglobin or the hemoglobin prior to transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative reduction in hematocrit</measure>
    <time_frame>Average of 3 days post-operatively</time_frame>
    <description>Measured as the pre-operative hematocrit minus the lowest post-operative hematocrit or the hematocrit prior to transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of units transfused</measure>
    <time_frame>Average of 3 days post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients transfused</measure>
    <time_frame>Average of 3 days post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep Vein Thrombosis</measure>
    <time_frame>30 days post-operative</time_frame>
    <description>Must be diagnosed via ultrasound duplex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>30 days post-operative</time_frame>
    <description>Must be diagnosed via CT chest or V/Q lung scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days post-operative</time_frame>
    <description>Must be diagnosed via CT scan or MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Blood Loss</condition>
  <condition>Anatomic Total Shoulder Arthroplasty</condition>
  <condition>Reverse Total Shoulder Arthroplasty</condition>
  <condition>Transfusion</condition>
  <condition>Tranexamic Acid</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group will be administered 1 gram tranexamic acid IV bolus (10 ml solution) 10 minutes prior to incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group will be administered 10 ml normal saline placebo IV bolus 10 minutes prior to incision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Tranexamic Acid Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient scheduled for a primary anatomic or reverse TSA

        Exclusion Criteria:

          -  Allergy to TXA

          -  Acquired disturbances of color vision

          -  Pre-op use of anticoagulant therapy within five days before surgery

          -  History of arterial or venous thromboembolic disease; such as DVT, PE, CVA, TIA

          -  Pregnancy or breastfeeding

          -  Recent MI (within 6 months of surgery) or any placement of stent regardless of time
             since placement

          -  Renal impairment

          -  Refusal of blood products

          -  Any patient undergoing a revision TSA

          -  Patients who decline to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yale A Fillingham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yale A Fillingham, MD</last_name>
    <phone>312-942-6000</phone>
    <phone_ext>3384</phone_ext>
    <email>yale_fillingham@rush.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yale A Fillingham, MD</last_name>
      <phone>312-942-6000</phone>
      <phone_ext>3384</phone_ext>
      <email>yale_fillingham@rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gregory Cvetanovich, MD</last_name>
      <phone>617-697-1261</phone>
      <email>gregory_cvetanovich@rush.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Saltzman BM, Chalmers PN, Gupta AK, Romeo AA, Nicholson GP. Complication rates comparing primary with revision reverse total shoulder arthroplasty. J Shoulder Elbow Surg. 2014 Nov;23(11):1647-54. doi: 10.1016/j.jse.2014.04.015.</citation>
    <PMID>24986694</PMID>
  </reference>
  <reference>
    <citation>Chalmers PN, Gupta AK, Rahman Z, Bruce B, Romeo AA, Nicholson GP. Predictors of early complications of total shoulder arthroplasty. J Arthroplasty. 2014 Apr;29(4):856-60. doi: 10.1016/j.arth.2013.07.002.</citation>
    <PMID>23927910</PMID>
  </reference>
  <reference>
    <citation>Gupta AK, Chalmers PN, Rahman Z, Bruce B, Harris JD, McCormick F, Abrams GD, Nicholson GP. Reverse total shoulder arthroplasty in patients of varying body mass index. J Shoulder Elbow Surg. 2014 Jan;23(1):35-42. doi: 10.1016/j.jse.2013.07.043.</citation>
    <PMID>24090984</PMID>
  </reference>
  <reference>
    <citation>Shields E, Iannuzzi JC, Thorsness R, Noyes K, Voloshin I. Perioperative complications after hemiarthroplasty and total shoulder arthroplasty are equivalent. J Shoulder Elbow Surg. 2014 Oct;23(10):1449-53. doi: 10.1016/j.jse.2014.01.052.</citation>
    <PMID>24751531</PMID>
  </reference>
  <reference>
    <citation>Yang ZG, Chen WP, Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am. 2012 Jul 3;94(13):1153-9. doi: 10.2106/JBJS.K.00873.</citation>
    <PMID>22623147</PMID>
  </reference>
  <reference>
    <citation>Gandhi R, Evans HM, Mahomed SR, Mahomed NN. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis. BMC Res Notes. 2013 May 7;6:184. doi: 10.1186/1756-0500-6-184.</citation>
    <PMID>23651507</PMID>
  </reference>
  <reference>
    <citation>Alshryda S, Mason J, Sarda P, Nargol A, Cooke N, Ahmad H, Tang S, Logishetty R, Vaghela M, McPartlin L, Hungin AP. Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H). J Bone Joint Surg Am. 2013 Nov 6;95(21):1969-74. doi: 10.2106/JBJS.L.00908.</citation>
    <PMID>24196467</PMID>
  </reference>
  <reference>
    <citation>Alshryda S, Mason J, Vaghela M, Sarda P, Nargol A, Maheswaran S, Tulloch C, Anand S, Logishetty R, Stothart B, Hungin AP. Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K). J Bone Joint Surg Am. 2013 Nov 6;95(21):1961-8. doi: 10.2106/JBJS.L.00907.</citation>
    <PMID>24196466</PMID>
  </reference>
  <reference>
    <citation>Ker K, Beecher D, Roberts I. Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database Syst Rev. 2013 Jul 23;(7):CD010562. doi: 10.1002/14651858.CD010562.pub2. Review.</citation>
    <PMID>23881695</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 21, 2016</lastchanged_date>
  <firstreceived_date>October 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Yale Fillingham</investigator_full_name>
    <investigator_title>Orthopaedic Surgery Resident</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
